Impact of 12/15-Lipoxygenase on Brain Injury After Subarachnoid Hemorrhage.
Animals
Arachidonate 12-Lipoxygenase
/ genetics
Arachidonate 15-Lipoxygenase
/ genetics
Brain Injuries
/ drug therapy
Disease Models, Animal
Isoxazoles
/ pharmacology
Lipoxygenase Inhibitors
/ pharmacology
Macrophages
/ enzymology
Mice
Mice, Knockout
Naphthalenes
/ pharmacology
Oxidative Stress
/ drug effects
Subarachnoid Hemorrhage
/ drug therapy
blood-brain barrier
brain injury
lipoxygenase
oxidative stress
subarachnoid hemorrhage
Journal
Stroke
ISSN: 1524-4628
Titre abrégé: Stroke
Pays: United States
ID NLM: 0235266
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
pubmed:
4
1
2019
medline:
17
10
2019
entrez:
4
1
2019
Statut:
ppublish
Résumé
Background and Purpose- Subarachnoid hemorrhage (SAH) is a devastating form of stroke. Oxidative stress contributes to brain injury, but the mechanisms have been poorly studied. Here, we evaluated the role of 12/15-lipoxygenase (12/15-LOX), an enzyme known to cause cell death in ischemic stroke, on brain injury in a mouse model of SAH. Methods- C57Bl6 wild-type mice and Alox15 knockout mice were subjected to SAH using a direct blood injection technique. In SAH wild-type mice, half received the 12/15-LOX inhibitor ML351 and half received vehicle. Immunohistochemistry, brain edema, blood-brain barrier leakage and functional outcomes were assessed 1 and 3 days after SAH induction. Results- SAH led to increased 12/15-LOX in macrophages of the brain parenchyma, adjacent to the subarachnoid blood. Neuronal cell death after SAH was reduced by ML351 and in Alox15 knockout mice. Similarly, SAH induced brain edema, which was 12/15-LOX dependent. Finally, Alox15 gene knockout and inhibitor treatment in wild-type mice with SAH led to an improved behavioral outcome. Conclusions- 12/15-LOX is overexpressed in macrophages after SAH in mice, and inhibition of the 12/15-LOX pathway decreases brain injury and improves neurological outcome. This study suggests 12/15-LOX as a novel therapeutic target to limit brain injury after SAH.
Identifiants
pubmed: 30602353
doi: 10.1161/STROKEAHA.118.022325
pmc: PMC6349484
mid: NIHMS1516142
doi:
Substances chimiques
Isoxazoles
0
Lipoxygenase Inhibitors
0
ML351 compound
0
Naphthalenes
0
Alox15 protein, mouse
EC 1.13.11.31
Arachidonate 12-Lipoxygenase
EC 1.13.11.31
Arachidonate 15-Lipoxygenase
EC 1.13.11.33
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
520-523Subventions
Organisme : NINDS NIH HHS
ID : R01 NS049430
Pays : United States
Organisme : NINDS NIH HHS
ID : R21 NS087165
Pays : United States
Références
J Neurosci Methods. 2005 Jun 15;144(2):257-63
pubmed: 15910986
Stroke. 1990 Feb;21(2):328-32
pubmed: 2106176
Stroke. 2012 Jun;43(6):1711-37
pubmed: 22556195
Brain Res. 2015 Jan 12;1594:245-55
pubmed: 25451085
J Cereb Blood Flow Metab. 2006 Nov;26(11):1341-53
pubmed: 16482081
Ann Neurol. 2013 Jan;73(1):129-35
pubmed: 23192915
J Neurosci Methods. 2014 May 30;229:44-52
pubmed: 24735531
J Med Chem. 2014 May 22;57(10):4035-48
pubmed: 24684213
J Cereb Blood Flow Metab. 2010 Jun;30(6):1157-67
pubmed: 20068575
Nat Rev Neurol. 2014 Jan;10(1):44-58
pubmed: 24323051
Stroke. 2006 Dec;37(12):3014-8
pubmed: 17053180
Mol Neurobiol. 2011 Feb;43(1):27-40
pubmed: 21161614